Immuron granted patent for anti-influenza product
Wednesday, 02 March, 2011
Melbourne-based Immuron scored a win today with the granting of an Australian patent for its influenza prevention product, Imm-255.
The patent, issued by the Australian Patents Office, provides protection through to 2028.
Imm-255 uses dairy-derived polyclonal influenza-specific antibodies, which are applied to oral and respiratory surfaces.
The antibodies have to date shown positive results in treating and preventing influenza in mice and ferrets, including treating H1N1.
Once animal trials have concluded, Immuron intends to proceed towards clinical trials in humans.
Immuron's (ASX:IMC) stock dropped $0.004 to 7.1c in morning trading.
RSV immunisation program for babies slashes hospital stays
An Australian-first study has demonstrated the effectiveness of immunisation against respiratory...
A targeted treatment option for psoriasis
New research from MedUni Vienna paves the way for the development of a therapy that not only...
Maternal cannabis use puts kids at risk of behavioural problems
Children exposed to their mother's cannabis use during pregnancy and after birth are three...
